As an immune-related tumor type, bladder cancer has been attracting much attention in the
study of its markers. In recent years, researchers have made rapid progress in the study of …

Bladder cancer (BLCA) is a most common urological tumours with high rate of recurrence,
which needs long‐term of follow‐up. To date, diagnosis and surveillance of BLCA still rely …

Due to bladder tumors' contact with urine, urine-derived cells (UDCs) may serve as a
surrogate for monitoring the tumor microenvironment (TME) in bladder cancer (BC) …

Intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) is a standard of care
therapy for non-muscle invasive bladder cancer (NMIBC), which accounts for about 75% of …

The short-lived nature and heterogeneity of Natural Killer (NK) cells limit the development of
NK cell-based therapies, despite their proven safety and efficacy against cancer. Here, we …

(1) Background: Inflammatory responses induce the formation of both anti-tumor and pro-
tumor neutrophils known as myeloid-derived suppressor cells (MDSCs). Intermittent …

Simple Summary A comprehensive characterization of cell subpopulations involved in the
immune response against bladder cancer has not been performed so far. In addition, due to …

The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant
cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing …

Intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) is a standard of care
therapy for non-muscle invasive bladder cancer (NMIBC), which accounts for about 75% of …

Bladder cancer patients receive frequent screening due to the high tumor recurrence rate
(more than 60%). Nowadays, the conventional monitoring method relies on cystoscopy …